Abstract: Statins are the first-line therapy prescribed to lower plasma cholesterol levels. Although being safe and showing several beneficial cholesterol-independent pleiotropic effects, a significant variability regarding statin's therapeutic goals has been abundantly documented, but less understood. We aimed to investigate the influence of the ABCC2 -24C>T single nucleotide polymorphism on Chilean hypercholesterolaemic individuals treated for 4 weeks with 10 mg/day atorvastatin. A total of 127 individuals medicated with atorvastatin 10 mg/day/4 weeks were included. Lipid profiles were determined before and after drug administration by conventional assays. Genotyping of the ABCC2 rs717620 SNP (-24C>T) was performed with TaqMan â Drug Metabolism Genotyping Assays. As expected, atorvastatin reduced TC, LDL-C and TG concentrations (p < 0.05). Also, HDL-C levels were increased (p < 0.05). Minor allele frequency for the rs717620 was 0.232. Overall, atorvastatin response was not associated with the ABCC2 rs717620 SNP (p > 0.05). Nonetheless, in male individuals carrying the -24T allele, we observed an attenuated reduction in both TG values and the TG/HDL-C ratio after 10 mg/day atorvastatin. This study indicates that TG levels and the TG/HDL-C ratio are affected by the rs717620 SNP in Chilean males but not female individuals after atorvastatin treatment.
The multidrug-resistance-associated protein (MRP2) is an anion transporter encoded by ABCC2, which is located in the apical membrane of different cell types such as enterocytes and hepatocytes, playing an important role in the excretion of xenobiotics and endogenous compounds [1] . This carrier is responsible for the regular efflux of organic anions through the cell membrane, which are conjugated with glutathione, glucuronic acid or sulphates in the bile or urine [2, 3] . The role of MRP2 has been widely demonstrated in patients with Dubin-Johnson syndrome (DJS), an inherited MRP2 deficiency caused by variations in the coding region of ABCC2, finally resulting in hyperbilirubinaemia [4] . Genetic variations within ABCC2 have also been associated with both risk of resistance [5] and adverse drug reactions (ADRs) to antiepileptic drugs [6, 7] . Different studies also show that polymorphisms within ABCC2 can result in alterations of both mRNA expression and MRP2 function [8, 9] . However, the functional effect of polymorphisms in the promoter region of ABCC2 is still controversial, and the mechanisms that alter its expression and transcriptional regulation in humans are unclear.
The common ABCC2 -24C>T variant, located in the 5 0 untranslated region (5 0 UTR), has been associated alone and as part of a common haplotype (-24C>T/-1019A>G/-1549G>A) with a 35% increase in promoter function compared to the reference sequence [3] . However, in vitro experiments of Laechelt et al. suggest that the -24T variant is associated with decreased activity of the MRP2 transporter [10] . Consequently, studies indicate that this polymorphism reduce protein activity in HepG2 cells by 18.7%, also observing a reduction in mRNA expression in renal tissue in individuals carrying this polymorphism [8, 11] . Statins competitively inhibit the enzyme 3-hydroxymethyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the rate-limiting enzymatic step for intrahepatic cholesterol biosynthesis [12] . Besides improving the lipid profile [13] , several studies indicate that statins display different cholesterol-independent effects, such as prevention of coronary artery disease (CAD) risk, reduction in inflammation, oxidative stress and atherosclerosis development [14, 15] and improved elasticity of blood vessels [16] , among others. In 2013, Ellis et al. [17] demonstrated that statins are substrates of human MRP2, and that their transport involved more than one binding site on the MRP2 protein. In addition, statins have been shown to increase MRP2 expression by a SREBP regulatory pathway in hepatocytes [18] . Also, in MRP2-deficient rats, Kivisto et al. [19] showed that biliary excretion of both oral and intravenous pravastatin was reduced, resulting in higher plasma concentrations, which was associated with a greater inhibitory effect on the HMG-CoA reductase enzyme. An investigation performed in the first cohort of the Rotterdam Study demonstrated that the ABCC2 -24C>T polymorphism was associated with ADRs, or with a too strong reduction in cholesterol levels [20] . Therefore, SNPs in ABCC2 may be modifying the pharmacokinetics of statins, hence, the response to pharmacological therapy. Consequently, we studied the effect of the ABCC2 -24C>T SNP on the lipid profile in Chilean hypercholesterolaemic individuals treated with 10 mg/day atorvastatin.
Materials and Methods
Individuals. A total of 127 (49 males, 78 females) unrelated Chilean individuals (55.9 AE 10.7 years) diagnosed with hypercholesterolaemia according to the NCEP criteria [21] and treated with 10 mg/day atorvastatin for 4 weeks were enrolled in this study. Patients were selected from the Federico Thieme Health Center (La Araucan ıa, Chile). Individuals with familial hypercholesterolaemia, and patients undergoing medication like diuretics, beta-blockers, concomitant hypolipemiant therapy and drugs that may alter the lipid profile were excluded. To identify potential adverse effects (AEs) associated with atorvastatin treatment, the leading physician evaluated every patient by examining laboratory determinations, looking also for symptoms such as headache, dizziness, nausea, constipation, diarrhoea and pain once the treatment was completed. The Ethics Committee of Universidad de La Frontera approved this study, and the protocols were developed in compliance with good laboratory practices. All patients agreed to participate voluntarily by signing a written informed consent.
Biochemical analysis. The lipid profile was determined in two blood samples obtained before and after atorvastatin treatment. Samples were collected by routine venous puncture in vacutainer tubes without anticoagulant after a 12-hr fast. An additional anticoagulated sample was obtained for molecular analysis. Biochemical determinations were performed with routine laboratory methods already described [22] . The LDL-C fraction was calculated using the Friedewald equation when triglycerides did not exceed 400 mg/dL [23] . The accuracy of each determination was controlled using normal and pathological commercial control serums (Human, Germany).
Molecular analysis. Extraction of genomic DNA was performed in peripheral leucocytes from an EDTA(1 mg/mL) anticoagulated blood sample using the procedure described by Salazar et al. [24] . DNA integrity was assessed by running a 1% agarose gel electrophoresis. Afterwards, DNA quantification was performed with an Infinite (R) M200 PRO (NanoQuant Tecan). Allelic discrimination of the promoter -24C>T polymorphism (ABCC2 rs717620 SNP) was completed using the C___2814642_10 TaqMan â Drug Metabolism
Genotyping Assay (Life Technologies, Carlsbad, CA, USA), according to the instructions provided by the manufacturer. Briefly, PCR assays contained 12.5 lL of Universal Master Mix (2X) (Life Technologies), 1.25 lL of TaqMan Drug Metabolism Genotyping Assay (20X) and 3 lL of DNA (20 ng/lL) diluted in nuclease-free water. The cycling protocol consisted in an initial 10-min. cycle at 95°C, followed by 40 cycles at 92°C for 10 sec., and 60°C for 1 min., using standard conditions for real-time system (Life Technologies). Genotype calling was performed with the plot issued by the StepOne software v. 2.2 (Life Technologies) after PCR amplification.
Statistical analysis. All statistical analyses were performed with the software GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, USA). Data are presented as mean AE S.D. Gaussian distribution of variables was assessed by Shapiro-Wilk normality test (a = 0.05). Allelic frequencies and genotype distribution were estimated by gene counting and tested for Hardy-Weinberg equilibrium. For the comparison of proportions and to evaluate the Hardy-Weinberg equilibrium, we used the chi-square test (v 2 ). To contrast lipid values prior and after atorvastatin therapy, the paired ttest was employed. As we observed a low number of individuals carrying the alternate allele homozygote, the influence of the genotypes on lipid values was assessed by clustering genotypes into a dominant inheritance model; then, genotypes were compared using Student's t-test for independent samples. We used the IBM SPSS Statistics for Windows, Version 22 (Armonk, NY: IBM Corp, USA) for multivariate analysis to perform a binary logistic regression analysis in order to exclude the influence of confounding variables on TG levels. The level of significance was set at p < 0.05. All analyses were two-sided.
Results
Individuals' demographics. Table 1 shows clinical and demographic characteristics of the 127 individuals evaluated before initiation of treatment. Hepatic enzymes were normal once the treatment was completed, and none of the individuals experienced ADRs. In general, atorvastatin was well tolerated by all individuals, and no atorvastatin-related ADRs were observed possibly due to the low dose employed. TC, LDL-C and TG values were significantly lower after the 4-week treatment. Also, atorvastatin improved significantly HDL-C levels (table 2). Table 3 shows allelic frequencies and genotype distribution for the ABCC2 rs717620 SNP. Genotypes were consistent with the HardyWeinberg equilibrium.
Response to atorvastatin and ABCC2 polymorphism. The overall effect of the ABCC2 -24C>T variant on lipid-lowering response to 10 mg/day atorvastatin is shown in table 4. In general, no associations were observed between atorvastatin treatment and the genetic variant studied. However, when analysing separately according to gender, we observed a significant effect of this SNP on TG values, finding a weaker TG reduction for men carrying the alternate allele (p = 0.0078, table 5). This effect was observed in males only. TG reduction was also highly variable among the patients ( fig. 1) . Out of male individuals located in the first quartile of TG reduction, that is achieving the highest reduction in TG, 85% (11 of 13) were normal homozygote carriers, while in the quartile showing the lowest TG reduction, 70% (nine of 13) carried the variant allele. Data analysis also revealed that the genotype was a significant independent predictor, regardless of age and BMI. Table 6 presents a logistic regression analysis for the variables influencing TG reduction in response to 10 mg/day atorvastatin treatment, showing that CC patients were 4.6 times more likely to benefit from atorvastatin therapy by having TG <150 mg/dL than patients with the T (CT + TT) allele. Figure 2 shows that patients with the T allele had a lower TG/HDL-C index reduction (À30.4% versus À41.5%, p = 0.030). This association was only observed in male individuals.
Discussion
In Chile, statins are the preferred lipid-lowering medication to lower cholesterol levels. However, response to treatment still constitutes a major pitfall in patients prescribed with these drugs. Several studies pinpoint the contribution of genetics to response variability observed after statin therapy, identifying multiple polymorphisms within key pharmacokinetics/pharmacodynamics genes associated with different lipid-lowering outcome. Accordingly, we previously showed a SNP in HMGCR affecting both LDL-C and HDL-C levels in response to atorvastatin [25] . Here, we aimed to determine the effect of the ABCC2 -24C>T SNP on the lipid profile of hypercholesterolaemic patients treated with 10 mg/day atorvastatin therapy. MRP2 is one of the transporters most associated with statins pharmacokinetics. This efflux transporter is highly polymorphic, causing large interindividual differences in both pharmacological response and toxicity. Lipid levels prior atorvastatin treatment showed no basal differences associated with the ABCC2 -24C>T SNP. The improvement in the lipid profile obtained after short-term low-dose atorvastatin is consistent with previous reports obtained by our group [13, 26] . However, regardless lower LDL-C levels after therapy, a wide range of response to the drug was also observed. At present, there are few studies that have characterized the functional impact of the promoter ABCC2 -24C>T polymorphism. Using cell-based reporter gene assays, Haenisch and colleagues demonstrated that this variant caused a 20% reduction in promoter activity [8] , while the presence of the haplotype -24C>T/1549G>A was shown to diminish promoter activity by 39% [27] . A decrease in promoter activity would in turn suggest lower ABCC2 expression; then, reduced transport for this substrate would be expected for individuals carrying the -24C>T variant, impairing atorvastatin excretion and thus, promoting a greater therapeutic response or the appearance of ADRs. In this study, we did not observe patients presenting any ADRs symptoms. However, this outcome may be limited due to only three patients carried the alternate homozygous genotype; thus, the lack of a bigger cohort prevented us from firmly confirming this scenario. Interestingly, we show a lower TG reduction associated with the -24T allele (CT+TT, p = 0.0078) in male but not female individuals, in which male patients carrying the wildtype homozygous -24CC are 4.6 times more likely to achieve proper TG levels goals (<150 mg/dL) rather than patients carrying the T allele (CT+TT) after atorvastatin therapy. To date, the effect of sex on both expression and activity of polymorphisms within MRP2 has not been properly studied. Nevertheless, it is known that there are sex-dependent differences affecting MRP2 expression due to oestrogens and androgens regulation, individual differences associated with genetic factors, as well as the specific type of tissue involved [28] [29] [30] . In the presence of this polymorphism, contradictory results have been reported [3, 10, 27] . MRP2 expression is regulated by a liver X receptor (LXR)-dependent pathway [31] . Previously, it has been described that LXR activation is responsible for the induction of fatty acid synthesis genes and stimulation of both synthesis and accumulation of triglycerides [32] . This is mediated by LXR-induced transcription of SREBP-1c, a sterol regulatory member. SREBP-1c induces transcription of different lipogenic genes, including fatty acid synthase and acetyl-CoA carboxylase, two key enzymes for de novo fatty acid synthesis [32] , but the effect of the ABCC2 -24C>TSNP on this pathway in the presence of atorvastatin has not yet been studied. Further investigations are needed to elucidate the possible mechanisms involved in our results.
We identified a significant variation in the TG/HDL-C index associated with the ABCC2 -24C>T polymorphism, where the polymorphic T allele displays lower TG reductions and a significantly lower reduction in the TG/HDL-C ratio. This attenuated decrease in the ratio might be indicating that male but not female patients with the T allele are at higher cardiovascular risk than those with the wild-type CC genotype. This sex-dependent effect can be explained due to TG and HDL cholesterol concentrations vary with gender [33] . However, as the TG/HDL-C ratio also varies according to race [34] , it becomes important to corroborate our results, especially to establish cut-off points that identify individuals at increased cardiovascular risk. Finally, within the limitations that we can mention, we should point out that the HWE is actually of borderline significance (0.055), which could be influencing the interpretation of our findings. We consider that a greater number of replicas could increase the statistical power to extract more solid conclusions. In addition, we must point out that the reduced sample size can count as an important limitation of the results shown. Thus, additional studies encompassing a bigger cohort are necessary to replicate our findings. In summary, our data showed that the promoter ABCC2 -24C>T SNP affects both TG levels and the TG/ HDL-C ratio after short-term low-dose atorvastatin treatment in male but not female hypercholesterolaemic individuals.
